Table 2.
Characteristics of patients eligible for Ribociclib.
| Number of Patients | Percentage | |
|---|---|---|
| 747 | 100% | |
| Age | 59.1 ± 13.0 | |
| Menopausal status | ||
| Premenopausal | 240 | 32.1 |
| Postmenopausal | 497 | 66.5 |
| Male | 3 | 0.4 |
| n/a | 7 | 0.9 |
| Histology | ||
| NST | 587 | 78.6 |
| ILC | 132 | 17.7 |
| Other | 28 | 3.7 |
| n/a | 0 | 0 |
| Grading | ||
| 1 | 24 | 3.2 |
| 2 | 508 | 68 |
| 3 | 215 | 28.8 |
| n/a | 0 | 0 |
| T-stage | ||
| 0 | 32 | 4.3 |
| 1 | 216 | 28.9 |
| 2 | 386 | 51.7 |
| 3 | 80 | 10.7 |
| 4 | 33 | 4.4 |
| N-stage | ||
| 0 | 206 | 27.6 |
| 1 | 415 | 55.6 |
| 2 | 89 | 11.9 |
| 3 | 37 | 5 |
| X | 0 | 0 |
| ER status | ||
| + | 740 | 99.1 |
| − | 7 | 0.9 |
| PR status | ||
| + | 607 | 81.3 |
| − | 140 | 18.7 |
| HER2 status | ||
| + | 0 | 0 |
| − | 747 | 100 |
| Ki67 | ||
| ≥20% | 399 | 53.4 |
| <20% | 348 | 46.6 |
| Chemotherapy | ||
| Neoadjuvant | 129 | 17.3 |
| Adjuvant | 240 | 32.1 |
| None | 378 | 50.6 |
NST, non-special type; ILC, invasive lobular carcinoma; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2; TNBC, triple-negative breast cancer; n/a, not available.